Global Valsartan-Hydrochlorothiazide Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Valsartan-Hydrochlorothiazide Market Research Report 2024
This drug is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This product contains two medicationsvalsartan and hydrochlorothiazide. Valsartan is an angiotensin receptor blocker (ARB) and works by relaxing blood vessels so that blood can flow more easily. Hydrochlorothiazide is a "water pill" (diuretic) that causes you to make more urine, which helps your body get rid of extra salt and water.
According to Mr Accuracy reports new survey, global Valsartan-Hydrochlorothiazide market is projected to reach US$ 800.5 million in 2029, increasing from US$ 541 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Valsartan-Hydrochlorothiazide market research.
Key manufacturers engaged in the Valsartan-Hydrochlorothiazide industry include Novartis, Teva, Lupin, Aurobindo Pharma, Torrent Pharmaceuticals, Par Pharmaceutical, Huaren Pharmaceutical, Mylan and Alembic Pharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Valsartan-Hydrochlorothiazide were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Valsartan-Hydrochlorothiazide market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Valsartan-Hydrochlorothiazide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novartis
Teva
Lupin
Aurobindo Pharma
Torrent Pharmaceuticals
Par Pharmaceutical
Huaren Pharmaceutical
Mylan
Alembic Pharmaceuticals
Zhejiang Huahai Pharmaceutical
APOTEX
MACLEODS
Chongqing Conquer Pharmaceutical
Beijing Second Pharmaceutical
Cisen Pharmaceutical
Segment by Type
Tablet
Capsule
Hospital
Drug Store
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Valsartan-Hydrochlorothiazide report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Valsartan-Hydrochlorothiazide market is projected to reach US$ 800.5 million in 2029, increasing from US$ 541 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Valsartan-Hydrochlorothiazide market research.
Key manufacturers engaged in the Valsartan-Hydrochlorothiazide industry include Novartis, Teva, Lupin, Aurobindo Pharma, Torrent Pharmaceuticals, Par Pharmaceutical, Huaren Pharmaceutical, Mylan and Alembic Pharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Valsartan-Hydrochlorothiazide were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Valsartan-Hydrochlorothiazide market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Valsartan-Hydrochlorothiazide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Teva
Lupin
Aurobindo Pharma
Torrent Pharmaceuticals
Par Pharmaceutical
Huaren Pharmaceutical
Mylan
Alembic Pharmaceuticals
Zhejiang Huahai Pharmaceutical
APOTEX
MACLEODS
Chongqing Conquer Pharmaceutical
Beijing Second Pharmaceutical
Cisen Pharmaceutical
Segment by Type
Tablet
Capsule
Segment by Application
Hospital
Drug Store
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Valsartan-Hydrochlorothiazide report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source